Druggability of the ubiquitin system: which road to take ?

27 févr. 2019
CEDOC - CHRONIC DISEASES RESEARCH CENTER R. Câmara Pestana 6, 1150-078 Lisboa, Portugal - Lisbonne (Portugal)


Post-translational modifications (PTM) by members of the Ubiquitin (Ub) family represent an efficient way to regulate almost every biological process. Defects in this homeostatic equilibrium, result in pathologies such as cancer, neurodegeneration, inflammation or multiple infections. For this reason, this research area has become very attractive for fundamental scientists as well as for the pharmaceutical industry aiming to identify potential targets for therapeutic intervention. Our one-day symposium will therefore focus on the potential developments with regards to the druggability of the ubiquitin system. Discussions will cover a wide range of topics, from genome instability and cancer to neurodegeneration, metabolic and infectious diseases.
Discipline scientifique : Chimie thérapeutique - Biochimie, Biologie Moléculaire - Biologie cellulaire - Biotechnologies - Cancer - Immunologie - Médecine humaine et pathologie - Neurosciences

Lieu de la conférence
Personnes connectées : 68 |  Contact |  À propos |  RSS